The $394.6M open-market buy by RA Capital at the IPO price of $20 is among the largest insider purchase clusters ever seen as a percentage of market cap. This signals that the company's largest pre-IPO holder is doubling down at the public listing price, providing a strong floor for the stock. Traders should watch for any lockup expiration (typically 180 days post-IPO) and monitor the Regeneron partnership for clinical catalysts. Short-term momentum from this signal should be expected.
Price Chart
Executive Summary
Parabilis Medicines insiders executed a massive $394.8M open-market purchase and converted millions of derivative shares for no cash on June 11, the same day the company closed its IPO and a $75M Regeneron PIPE. The $394.6M buy by RA Capital Management (a 10% owner/director) represents ~12.3% of the $3.2B market cap, an extraordinarily high conviction signal. Directors also received routine equity grants, and a second director bought $250K worth of shares. The strong alignment between the Regeneron strategic investment, the IPO closing, and insider buying indicates insiders are putting significant capital at risk at the $20/share price.
Key Financial Metrics
Key Facts
- RA Capital Management bought 19.73M shares at $20/share for $394.6M in an open-market purchase, representing ~12.3% of market cap.
- Multiple directors converted derivative securities into common shares for $0 (non-cash) on June 11, the same day as the IPO closing.
- Director Alan Sebulsky bought 12,500 shares at $20 for $250K in an open-market purchase.
- The insider cluster coincided with the company's IPO and a $75M Regeneron private placement announced June 11.
- Six directors received equity grants (20K shares each, non-cash) on June 9, three days before the insider buying cluster.
Financial Impact
Insider purchases totaling $394.8M (12.3% of market cap) at $20/share, signaling extreme conviction from the largest shareholder and a director.
Risk Factors
- Lockup agreements will prevent any insider selling for at least 180 days, creating a potential overhang when they expire.
- The company is a pre-revenue biotech (implied by recent IPO) with no approved products or revenue stream mentioned in the filing.
- Dilution risk from the 4.17M shares issued to Regeneron at a 10% discount to IPO price.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PBLS-1781564346657 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 2d ago | Press Release | $24.79 | awaiting T+60 | — | $25.27 (+1.96%) |
Oct 19, 2026 7d ago | Press Release | $25.35 | awaiting T+60 | — | $25.27 (−0.30%) |
Sep 15, 2026 5w ago | 8-K | $36.88 | awaiting T+60 | — | $25.27 (−31.47%) |
Sep 2, 2026 7w ago | 8-K | $40.75 | awaiting T+60 | — | $25.27 (−37.98%) |
Aug 13, 2026 10w ago | 8-K | $35.67 | awaiting T+60 | — | $25.27 (−29.14%) |
Aug 13, 2026 10w ago | Press Release | $35.67 | awaiting T+60 | — | $25.27 (−29.14%) |
Jul 22, 2026 13w ago | Insider Buy | $32.81 $22.75 | ▼ −30.66% | ▼ −34.31% | $25.27 (−22.97%) |
Jun 29, 2026 17w ago | Insider Cluster | $29.19 $33.31 | ▲ +14.11% | ▲ +10.50% | $25.27 (−13.41%) |
Jun 16, 2026 18w ago | Insider Cluster | $26.03 $36.16 | ▲ +38.92% | ▲ +36.23% | $25.27 (−2.90%) |
Jun 15, 2026 18w ago | Insider Cluster | $26.59 $36.88 | ▲ +38.70% | ▲ +36.84% | $25.27 (−4.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers